ALDX Stock Price, Aldeyra Therapeutics Inc Quote, Chart

Market Summary

USD3.91-0.02

Market Closed

-0.51%

ALDX Alerts

1 major insider buys recently.

ALDX Stock Price

View Fullscreen

ALDX RSI Chart

ALDX Valuation

Market Cap

230.3M

Price/Earnings (Trailing)

-6.13

EV/EBITDA

-1.56

Price/Free Cashflow

-7.59

MarketCap/EBT

-3.92

ALDX Price/Sales (Trailing)

ALDX Profitability

Return on Equity

-31.34%

Return on Assets

-25.31%

Free Cashflow Yield

-13.17%

ALDX Fundamentals

ALDX Earnings

Earnings (TTM)

-37.5M

Earnings Growth (Yr)

63.16%

Earnings Growth (Qtr)

41.94%

Breaking Down ALDX Revenue

Last 7 days

1.0%

Last 30 days

34.8%

Last 90 days

30.3%

Trailing 12 Months

-58.6%

How does ALDX drawdown profile look like?

ALDX Financial Health

Current Ratio

6.64

ALDX Investor Care

Shares Dilution (1Y)

0.55%

Diluted EPS (TTM)

-0.37

Tracking the Latest Insider Buys and Sells of Aldeyra Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	perceptive advisors llc	bought	178,755	4.74	37,712	-
Apr 04, 2024	perceptive advisors llc	bought	655,112	4.67	140,281	-
Apr 03, 2024	perceptive advisors llc	bought	1,267,270	4.09	309,847	-
Apr 02, 2024	perceptive advisors llc	bought	640,015	3.44	186,051	-
Apr 01, 2024	perceptive advisors llc	bought	27,215	3.25	8,374	-
Mar 12, 2024	brady todd c	sold	-260,238	3.05	-85,324	president and ceo
Mar 12, 2024	machatha stephen	sold	-36,503	3.164	-11,537	chief development officer
Mar 11, 2024	machatha stephen	sold	-62,102	3.4064	-18,231	chief development officer
Mar 11, 2024	greenberg bruce	sold	-44,967	3.4064	-13,201	see remarks

Which funds bought or sold ALDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-78,239	86,630	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	9.88	2,726	117,798	-%
Apr 19, 2024	DENALI ADVISORS LLC	new	-	154,671	154,671	0.05%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-42,783	-	-%
Apr 17, 2024	Stephens Consulting, LLC	unchanged	-	-240	3,270	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	2.5	-12,544	265,452	0.01%
Apr 15, 2024	KINGSWOOD WEALTH ADVISORS, LLC	new	-	49,050	49,050	0.01%
Apr 11, 2024	INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	added	3.08	-8,154	197,181	0.02%
Apr 09, 2024	WOODSTOCK CORP	added	46.28	148,607	558,238	0.06%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	240	853,019	1,245,130	-%

Are Funds Buying or Selling ALDX?

Are funds buying ALDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALDX

No. of Funds

ALDX Alerts

1 major insider buys recently.

Unveiling Aldeyra Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perceptive advisors llc	14.6%	8,593,586	SC 13G/A
Feb 13, 2024	vanguard group inc	6.68%	3,927,597	SC 13G
Jan 29, 2024	blackrock inc.	5.8%	3,430,774	SC 13G
Oct 19, 2023	perceptive advisors llc	14.7%	8,593,586	SC 13G/A
Oct 04, 2023	knoll capital management, llc	6.1%	3,595,916	SC 13G
Feb 14, 2023	perceptive advisors llc	19.4%	11,350,085	SC 13G/A
Feb 03, 2023	state street corp	0.30%	173,281	SC 13G/A
Jul 08, 2022	blackrock inc.	1.7%	974,947	SC 13G
Feb 14, 2022	perceptive advisors llc	17.0%	9,903,879	SC 13G/A
Feb 09, 2022	state street corp	5.31%	3,082,352	SC 13G

Recent SEC filings of Aldeyra Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 17, 2024	4/A	Insider Trading
Apr 17, 2024	4/A	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 28, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Aldeyra Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Aldeyra Therapeutics Inc News

Latest updates

Aldeyra Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	0.7%	148	147	156	168	181	190	201	223	233	247	256	147	83.00	88.00	72.00	63.00	76.00	77.00	74.00	88.00	95.00
Current Assets	0.4%	148	147	155	168	181	189	201	222	233	247	256	147	83.00	88.00	71.00	63.00	75.00	77.00	73.00	87.00	95.00
Cash Equivalents	-0.4%	143	143	152	165	144	129	121	159	230	241	250	138	78.00	86.00	61.00	39.00	44.00	52.00	39.00	44.00	47.00
Net PPE	-25.9%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	17.5%	29.00	24.00	26.00	31.00	30.00	27.00	27.00	32.00	27.00	28.00	23.00	21.00	24.00	19.00	19.00	20.00	27.00	27.00	7.00	10.00	8.00
Current Liabilities	3.0%	22.00	22.00	16.00	16.00	15.00	24.00	16.00	16.00	12.00	12.00	7.00	11.00	12.00	6.00	5.00	5.00	13.00	12.00	6.00	9.00	8.00
Long Term Debt	-100.0%	-	3.00	10.00	15.00	15.00	3.00	11.00	16.00	16.00	15.00	15.00	10.00	11.00	13.00	14.00	15.00	15.00	14.00	-	-	-
LT Debt, Current	12.5%	15.00	13.00	6.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	3.00	10.00	15.00	15.00	3.00	11.00	16.00	16.00	15.00	15.00	10.00	11.00	13.00	14.00	15.00	15.00	14.00	-	-	-
Shareholder's Equity	-2.6%	120	123	130	137	151	162	174	191	206	220	234	126	60.00	69.00	53.00	43.00	48.00	51.00	67.00	78.00	87.00
Retained Earnings	-1.2%	-394	-389	-381	-372	-356	-343	-329	-311	-294	-278	-263	-248	-236	-225	-216	-209	-199	-186	-167	-154	-138
Additional Paid-In Capital	0.3%	514	512	511	510	508	506	504	502	500	499	497	374	296	295	270	253	247	237	235	233	225
Shares Outstanding	0.0%	59.00	59.00	59.00	59.00	59.00	58.00	58.00	58.00	58.00	53.00	54.00	46.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	483	-	-	-	228	-	-	-	649	-	-	-	128	-	-	-	153	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	106.2%	500	-8,024	-13,357	-9,443	-11,231	-12,574	-19,958	-12,873	-11,577	-8,434	-9,072	-13,471	-8,317	-6,237	-7,579	-15,359	-11,226	-8,315	-12,810	-12,631	-7,968
Share Based Compensation	-201.4%	-800	789	1,574	4,190	2,821	2,237	1,294	1,937	984	1,418	2,324	2,382	1,630	1,757	1,742	1,954	1,949	2,153	2,095	1,886	1,018
Cashflow From Investing	-	-	-	-	30,000	27,000	19,016	-17,938	-58,031	-	-	-	-7.81	-	5,500	17,300	6,224	-4,285	5,676	7,922	9,164	-28,972
Cashflow From Financing	-220.6%	-1,012	-315	5.00	53.00	-	1,197	-	23.00	-	64.00	120,369	74,064	1*	26,224	12,425	3,253	8,333	14,844	-9.14	408	66,289

ALDX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 29,458,719	$ 47,306,066
General and administrative	13,335,364	15,373,921
Loss from operations	(42,794,083)	(62,679,987)
Other income (expense):
Interest income	7,323,008	2,349,449
Interest expense	(2,071,435)	(1,694,098)
Total other income, net	5,251,573	655,351
Net loss	$ (37,542,510)	$ (62,024,636)
Net loss per share - basic	$ (0.64)	$ (1.06)
Net loss per share - diluted	$ (0.64)	$ (1.06)
Weighted average common shares outstanding - basic	58,943,205	58,405,897
Weighted average common shares outstanding - diluted	58,943,205	58,405,897

ALDX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 142,823,016	$ 144,419,364
Marketable securities	0	29,881,520
Prepaid expenses and other current assets	4,987,317	6,722,229
Total current assets	147,810,333	181,023,113
Fixed assets, net	5,764	19,279
Right-of-use assets	510,814	249,265
Total assets	148,326,911	181,291,657
Current liabilities:
Accounts payable	1,338,057	133,625
Accrued expenses	5,536,464	14,065,885
Current portion of long-term debt	15,146,546	911,763
Operating lease liabilities	239,183	249,265
Total current liabilities	22,260,250	15,360,538
Deferred collaboration revenue, long-term	6,000,000	0
Operating lease liabilities, long-term	271,631	0
Long-term debt, net of current portion	0	14,923,090
Total liabilities	28,531,881	30,283,628
Commitments and contingencies (Notes 3 & 13)
Stockholders' equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued and outstanding	0	0
Common stock, voting, $0.001 par value; 150,000,000 authorized and 59,195,951 and 58,560,078 shares issued and outstanding, respectively	59,196	58,560
Additional paid-in capital	513,994,982	507,770,045
Accumulated other comprehensive income	0	(103,938)
Accumulated deficit	(394,259,148)	(356,716,638)
Total stockholders’ equity	119,795,030	151,008,029
Total liabilities and stockholders’ equity	$ 148,326,911	$ 181,291,657

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

CEO	Dr. Todd C. Brady M.D., Ph.D.
WEBSITE	aldeyra.com
INDUSTRY	Biotechnology
EMPLOYEES	15

Aldeyra Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aldeyra Therapeutics Inc? What does ALDX stand for in stocks?

ALDX is the stock ticker symbol of Aldeyra Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aldeyra Therapeutics Inc (ALDX)?

As of Tue Apr 23 2024, market cap of Aldeyra Therapeutics Inc is 230.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALDX stock?

You can check ALDX's fair value in chart for subscribers.

What is the fair value of ALDX stock?

You can check ALDX's fair value in chart for subscribers. The fair value of Aldeyra Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aldeyra Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aldeyra Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALDX is over valued or under valued. Whether Aldeyra Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aldeyra Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALDX.